Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.05EUR
−176.62 MEUR
148.00 MEUR
55.83 M
About DECIPHERA PHARMACEUTICALS INC
Sector
Industry
CEO
Steven L. Hoerter
Website
Headquarters
Waltham
Employees (FY)
355
Founded
2003
FIGI
BBG00J2CPYS7
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of D05 is 23.80 EUR — it has increased by 0.85% in the past 24 hours. Watch DECIPHERA PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange DECIPHERA PHARMACEUTICALS INC stocks are traded under the ticker D05.
We've gathered analysts' opinions on DECIPHERA PHARMACEUTICALS INC future price: according to them, D05 price has a max estimate of 28.03 EUR and a min estimate of 23.92 EUR. Watch D05 chart and read a more detailed DECIPHERA PHARMACEUTICALS INC stock forecast: see what analysts think of DECIPHERA PHARMACEUTICALS INC and suggest that you do with its stocks.
D05 stock is 0.85% volatile and has beta coefficient of 1.49. Track DECIPHERA PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is DECIPHERA PHARMACEUTICALS INC there?
Today DECIPHERA PHARMACEUTICALS INC has the market capitalization of 2.07 B, it has increased by 0.99% over the last week.
Yes, you can track DECIPHERA PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
DECIPHERA PHARMACEUTICALS INC is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
D05 earnings for the last quarter are −0.48 EUR per share, whereas the estimation was −0.51 EUR resulting in a 6.19% surprise. The estimated earnings for the next quarter are −0.47 EUR per share. See more details about DECIPHERA PHARMACEUTICALS INC earnings.
DECIPHERA PHARMACEUTICALS INC revenue for the last quarter amounts to 41.98 M EUR, despite the estimated figure of 42.82 M EUR. In the next quarter, revenue is expected to reach 46.43 M EUR.
D05 net income for the last quarter is −41.78 M EUR, while the quarter before that showed −42.75 M EUR of net income which accounts for 2.27% change. Track more DECIPHERA PHARMACEUTICALS INC financial stats to get the full picture.
No, D05 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 29, 2024, the company has 355.00 employees. See our rating of the largest employees — is DECIPHERA PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DECIPHERA PHARMACEUTICALS INC EBITDA is −185.44 M EUR, and current EBITDA margin is −125.12%. See more stats in DECIPHERA PHARMACEUTICALS INC financial statements.
Like other stocks, D05 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DECIPHERA PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DECIPHERA PHARMACEUTICALS INC technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DECIPHERA PHARMACEUTICALS INC stock shows the buy signal. See more of DECIPHERA PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.